Richard Bethlehem is a postdoctoral fellow and research associate at the Autism Research Centre and Brain Mapping Unit at the University of Cambridge in the United Kingdom. He studies integrated neuroimaging and transcriptomics to gain better understanding of the biological underpinnings of typical and atypical neurodevelopment.
Richard Bethlehem
Research associate
University of Cambridge
From this contributor
Q&A with Richard Bethlehem: What goes into a Brainhack
Brainhack conferences offer talks and hands-on tutorials, and unite small groups of interdisciplinary researchers to work on open-source neuroscience projects.
Q&A with Richard Bethlehem: What goes into a Brainhack
How normative modeling can reframe autism’s heterogeneity
Normative modeling could capture variability among autistic people and allow for individualized assessments.
How normative modeling can reframe autism’s heterogeneity
Explore more from The Transmitter
To understand decision-making, we need to truly challenge lab animals
Complex, multidimensional tasks that unfold over time could reveal how different brain areas work together to support decisions.
To understand decision-making, we need to truly challenge lab animals
Complex, multidimensional tasks that unfold over time could reveal how different brain areas work together to support decisions.
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.